Facioscapulohumeral Muscular Dystrophy (FSHD) is an autosomal dominant myopathy characterized by progressive weakening of the facial, shoulder, and upper arm muscles. FSHD is not caused by a mutation in a protein-encoding gene;instead the genetic lesion in >98% of cases is a contraction in the number of non-coding D4Z4 DMA repeats specifically on chromosome 4q35. How this genome deletion leads to pathology is not understood, however, strong evidence indicates that genes localized proximal to the 4q35 deletion are mis-expressed in FSHD affected skeletal muscles. One such gene is FRG1 (FSHD region gene 1) the first transcribed gene identified that localized to 4q35 and the best overall candidate for mediating the pathology of FSHD. The FRG1 gene is conserved from C. elegans to humans, but still very little is known about the function of the FRG1 protein (FRG1P) in any system. This proposal directly addresses the nuclear function of FRG1P and the effects of misregulation of FRG1P expression levels in a novel vertebrate model for FSHD. The system for these studies is the vertebrate developmental model organism, Xenopus laevis (African clawed frog). Xenopus, with its external development and the ease of generating large numbers of transgenic animals, is ideal among available model systems for investigating FRGIP's role in FSHD pathogenesis.
In Aim 1 the transgenic FSHD-like animals will be further characterized for an FSHD pehntype in regards to muscle structure, physical characteristics, and behavior.
Aim 2 directly address function of FRG1P by using transgenic frogs to alter the expression levels of FRG1P domains during development, identifying the molecular mechanism of FSHD pathology. Proteins and nucleic acids that interact with FRG1P will be identified in Aim3. Ultimately, the goal of FSHD research is to find treatments. The epigenetic mis-regulation in FSHD will be extremely difficult to adress. The best viable targets for therapy are the affected gene (FRG1) or its downstream targets. An extension of Aim 1 proposes to test the FSHD-like frogs for thier ability to have the FSHD phenotype reversed or at leased lessened by reducing or eliminating FRG1 over-expression. Success of this line of experiments will indicate the feasibility of a small molecule screen for FSHD treatments. Xenopus FSHD-tadpoles develop externally and are transparent rendering them ideal for testing small molecule therapeutics to find a cure for FSHD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR055877-03
Application #
7673872
Study Section
Special Emphasis Panel (ZNS1-SRB-E (22))
Program Officer
Nuckolls, Glen H
Project Start
2007-09-01
Project End
2010-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
3
Fiscal Year
2009
Total Cost
$249,796
Indirect Cost
Name
University of Illinois Urbana-Champaign
Department
Anatomy/Cell Biology
Type
Schools of Arts and Sciences
DUNS #
041544081
City
Champaign
State
IL
Country
United States
Zip Code
61820
Jones, Takako I; Parilla, Megan; Jones, Peter L (2016) Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD). PLoS One 11:e0150938
Himeda, Charis L; Debarnot, CĂ©line; Homma, Sachiko et al. (2014) Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene. Mol Cell Biol 34:1942-55
Jones, Takako Iida; Chen, Jennifer C J; Rahimov, Fedik et al. (2012) Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. Hum Mol Genet 21:4419-30
Sun, Chia-Yun Jessica; van Koningsbruggen, Silvana; Long, Steven W et al. (2011) Facioscapulohumeral muscular dystrophy region gene 1 is a dynamic RNA-associated and actin-bundling protein. J Mol Biol 411:397-416
Hanel, Meredith L; Sun, Chia-Yun Jessica; Jones, Takako I et al. (2011) Facioscapulohumeral muscular dystrophy (FSHD) region gene 1 (FRG1) is a dynamic nuclear and sarcomeric protein. Differentiation 81:107-18
Wuebbles, Ryan D; Long, Steven W; Hanel, Meredith L et al. (2010) Testing the effects of FSHD candidate gene expression in vertebrate muscle development. Int J Clin Exp Pathol 3:386-400
Liu, Qian; Jones, Takako Iida; Tang, Vivian W et al. (2010) Facioscapulohumeral muscular dystrophy region gene-1 (FRG-1) is an actin-bundling protein associated with muscle-attachment sites. J Cell Sci 123:1116-23
Hanel, Meredith L; Wuebbles, Ryan D; Jones, Peter L (2009) Muscular dystrophy candidate gene FRG1 is critical for muscle development. Dev Dyn 238:1502-12
Wuebbles, Ryan D; Hanel, Meredith L; Jones, Peter L (2009) FSHD region gene 1 (FRG1) is crucial for angiogenesis linking FRG1 to facioscapulohumeral muscular dystrophy-associated vasculopathy. Dis Model Mech 2:267-74